Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
Phase 1
Terminated
- Conditions
- Locally Advanced Lung CarcinomaSolid TumorNon-Small Cell Lung CarcinomaSmall Cell Lung CarcinomaStage III Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8
- Interventions
- Procedure: Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT03735095
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1
Withdrawn
- Conditions
- Stage III Primary Peritoneal Cancer AJCC v8Stage IIIA Primary Peritoneal Cancer AJCC v8Stage IIIB Fallopian Tube Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Stage IVB Fallopian Tube Cancer AJCC v8Stage IVB Primary Peritoneal Cancer AJCC v8Stage II Fallopian Tube Cancer AJCC v8Stage II Ovarian Cancer AJCC v8Stage II Primary Peritoneal Cancer AJCC v8
- Interventions
- Biological: Alpha-type-1 Polarized Dendritic CellsBiological: Autologous Natural Killer Cell-like CTLs
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT03735589
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Phase 1
Terminated
- Conditions
- Locally Advanced Head and Neck CarcinomaRecurrent Head and Neck Carcinoma
- Interventions
- Procedure: Interstitial Illumination Photodynamic TherapyOther: Quality of Life Assessment
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT03727061
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
Phase 1
Terminated
- Conditions
- Advanced Cutaneous Melanoma of the ExtremityAdvanced Sarcoma of the ExtremityPathologic Stage IIIB Cutaneous Melanoma AJCC v8Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Recurrent Cutaneous Melanoma of the ExtremityRecurrent Sarcoma of the ExtremityStage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Interventions
- Drug: FACT Complex-targeting Curaxin CBL0137
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT03727789
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1
Withdrawn
- Conditions
- Metastatic Prostate Carcinoma in the Soft TissuePSA ProgressionCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Prostate Carcinoma Metastatic in the BonePSA Level Greater Than or Equal to Two
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT03709550
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1
Active, not recruiting
- Conditions
- Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRefractory Ovarian CarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Primary Peritoneal CarcinomaRefractory Fallopian Tube Carcinoma
- Interventions
- Biological: Autologous NY-ESO-1-specific CD8-positive T LymphocytesOther: Cellular Therapy
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT03691376
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Art in Improving Outcomes in Participants Undergo Surgery
Not Applicable
Terminated
- Conditions
- Health Status Unknown
- Interventions
- Procedure: Art TherapyOther: Best PracticeOther: Questionnaire Administration
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT03688945
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2
Completed
- Conditions
- Recurrent Fallopian Tube CarcinomaOvarian Serous TumorRecurrent Primary Peritoneal CarcinomaFallopian Tube Serous NeoplasmOvarian Clear Cell TumorOvarian Mucinous TumorFallopian Tube Endometrioid TumorFallopian Tube Mucinous NeoplasmOvarian Endometrioid TumorRecurrent Ovarian Carcinoma
- Interventions
- Other: Laboratory Biomarker AnalysisDevice: Monitoring DeviceOther: Physical ActivityOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT03685695
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer
Not Applicable
Completed
- Conditions
- Stage IV Breast Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisBehavioral: Meditation-Based Stress Reduction ProgramOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 44
- Registration Number
- NCT03683147
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Informational Intervention in Increasing Lactation Practices by African American Women
Not Applicable
Completed
- Conditions
- Healthy SubjectPregnant
- Interventions
- Other: Informational InterventionOther: InterviewOther: Survey Administration
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 296
- Registration Number
- NCT03680235
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States